Cas:135548-15-1 Oxeclosporin manufacturer & supplier

Chemical Name:Oxeclosporin

CAS.NO:135548-15-1

Synonyms:sdz imm 125

Molecular Formula:C₆₄H₁₁₅N₁₁O₁₄

Molecular Weight:1262.66000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:1334.8ºC at 760mmHg

Density:1.033g/cm3

Index of Refraction:1.47

PSA:308.26000

Exact Mass:1261.86000

LogP:3.48610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like sdz imm 125 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,sdz imm 125 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,sdz imm 125 Use and application,sdz imm 125 technical grade,usp/ep/jp grade.

Related News: We partner with life science companies of all sizes, drawing on over 20 years of industry experience. Oxeclosporin manufacturer Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control. Oxeclosporin supplier A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. Oxeclosporin vendor China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. Oxeclosporin factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.